Expression of serum TK1 in human breast tumor and its clinical significance

任若冰; 许頳; 李亚芬; 金冶宁; 何建蓉

doi:10.3969/j.issn.1007-3969.2014.01.007

您当前的位置：

首页 >

文章列表页 >

Expression of serum TK1 in human breast tumor and its clinical significance

更新时间：2025-12-31

- Expression of serum TK1 in human breast tumor and its clinical significance
- China Oncology Vol. 24, Issue 1, Pages: 41-45(2014)
- 作者机构：
  
  上海交通大学医学院附属瑞金医院乳腺疾病诊治中心,上海,200025
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.01.007
  CLC：
- Published Online：14 February 2014，
  
  Published：14 February 2014
- 稿件说明：
移动端阅览
任若冰,许頳,李亚芬,金冶宁,何建蓉. 血清胸苷激酶1在乳腺肿瘤中的表达及其临床意义[J]. 中国癌症杂志, 2014, 24(1): 41-45.

任若冰, 许頳, 李亚芬, et al. Expression of serum TK1 in human breast tumor and its clinical significance[J]. China Oncology, 2014, 24(1): 41-45.
任若冰,许頳,李亚芬,金冶宁,何建蓉. 血清胸苷激酶1在乳腺肿瘤中的表达及其临床意义[J]. 中国癌症杂志, 2014, 24(1): 41-45. DOI： 10.3969/j.issn.1007-3969.2014.01.007.

任若冰, 许頳, 李亚芬, et al. Expression of serum TK1 in human breast tumor and its clinical significance[J]. China Oncology, 2014, 24(1): 41-45. DOI： 10.3969/j.issn.1007-3969.2014.01.007.

摘要

背景与目的：胸苷激酶1(thymidine kinase 1，TK1)在细胞分裂期的细胞质中表达，是将脱氧胸苷转换为胸苷酸的催化酶，是嘧啶补救途径的关键酶。本研究探讨TK1在乳腺肿瘤患者血清中的表达及其临床意义。方法：收集上海交通大学医学院附属瑞金医院乳腺疾病诊治中心145例乳腺癌患者(乳腺癌组)，55例乳腺纤维腺瘤患者(乳腺纤维腺瘤组)，采用化学发光斑点杂交法检测两组患者的血清TK1水平，并分析血清TK1水平与各个临床病理特征的关系。结果：乳腺癌组血清TK1水平为(2.749±0.122)pmol/L，乳腺纤维腺瘤组为(1.319±0.126)pmol/L，差异有统计学意义(P0.000 1)。在乳腺癌患者中，淋巴结晚期(P=0.049)、有远处转移(P=0.003 1)、TNM分期晚期(P=0.01)的血清TK1水平明显升高。乳腺超声(P0.001)，乳腺磁共振(P=0.005)，乳腺钼靶(P=0.032)BI-RADS分类为恶性(4C-6)的患者的TK1水平高于良性(0-4B)患者。雌激素受体高表达的乳腺癌患者的TK1水平高于低表达的患者(P=0.034)。在不同的年龄、分化程度、肿块大小及其他激素受体情况差异无统计学意义(P0.05)。随访2年后未发现TK1水平与无进展生存期的相关性，差异无统计学意义(P=0.7061)。结论：血清TK1在乳腺癌的早期诊断，预测预后有重要价值，并可能成为新的分子靶向治疗的基础。

Abstract

Background and purpose: The position of thymidine kinase 1 (TK1) expression during cell division is in the cytoplasm. It is a catalytic enzyme to convert deoxythymidine into thymidylate. It is the key enzyme of pyrimidine salvage pathway. The aim of this study was to analyze the serum expression level of TK1 in patients with breast cancer

and explore the application of serum TK1 test in clinical assessments of diagnosis

treatment and prognosis for breast cancer. Methods: Patient data were collected from the patients admitted in Comprehensive Breast Health Center at Rui Jin Hospital. Chemiluminesence dot blot assay was used to detect serum TK1 levels in 145 breast cancer patients and 55 patients with breast fibroadenoma. The correlations of serum TK1 levels with breast tumor biological behavior was further studied. Results: Serum TK1 expression levels was significantly increased in breast cancer patients [(2.749±0.122)pmol/L] when compared to breast fibroadenoma patients[(1.319±0.126)pmol/L

P0.000 1]. Serum TK1 levels were statistically increased in patients with lymph node metastasis (P=0.049)

distal metastasis (P=0.003 1)

and late TNM stages (P=0.01). No serum TK1 level differences were found in patients with different ages (P0.05)

different tumor grades (P=0.453) and different tumor size (P=0.908). Preoperative imaging results including breast ultrasound

breast mammography and breast magnetic resonance were analyzed by assessments of BI-RADS category

and serum TK1 levels in patients with different BI-RADS categories were studied. Serum TK1 levels in patients with breast ultrasound BI-RADS categories 4C-6 were significantly higher than those with category 0-4B (P0.001). Consistently

the serum TK1 levels in patients with MR BI-RADS categories 4C-6 were higher than categories 0-4B (P=0.005). The serum TK1 levels in patients with mammography BI-RADS categories 4C-6 were higher than categories 0-4B (P=0.032). The serum TK1 levels were significantly increased in patients with ER high expression in breast tumor tissues than those with low expression (P=0.034). Serum TK1 levels had no differences in patients with different expression levels of PR

HER-2 and MIB-1 (P0.05). Most patients were followed up in our outpatient department for about 2 years. No progression-free survival differences were found in 2years. Conclusion: Serum TK1 test might be a potential tool for screening

prognosis determination and effect evaluations of targeted therapy in breast carcinoma.

关键词

Keywords

references

Views

4869

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Exploration of the efficacy and safety of indocyanine green in the evaluation and localization of breast cancer surgical margins: a single-center, observational cohort study

Artificial intelligence in gastric cancer diagnosis, treatment and prognostic prediction: current application and future perspective

The unique value and controversy of nuclear medicine molecular imaging in the evaluation of radioiodine-refractory differentiated thyroid cancer

China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition)

Related Author

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

Gang LÜ

Guangqing WANG

Yan ZHENG

Qin TANG

Fei CHEN

Xudong YU

Related Institution

Department of Thyroid and Breast Surgery, The Fourth Affiliated Hospital of Anhui Medical University (Affiliated Chaohu Hospital)

Pathology Department, The Fourth Affiliated Hospital of Anhui Medical University (Affiliated Chaohu Hospital)

General Practice, Hefei First People’s Hospital

Department of Oncology, Xinjiang Military Region General Hospital of the Chinese People’s Liberation Army, Urumqi 830000, Xinjiang Uygur Autonomous Region

Graduate School of Xinjiang Medical university, Urumqi 830000, Xinjiang Uygur Autonomous Region

AI问答

⁰